Proton Partners International to fight cancer with Elekta radiotherapy equipment

CRAWLEY, UK, November 30 – Elekta (EKTA-B.ST) is to help Proton Partners
International achieve its goal of creating hubs of excellence for advanced
cancer treatment in the UK by providing the latest technology in radiotherapy.
Proton Partners International is to open centers in the UK. In addition to
proton therapy, the centers will offer radiotherapy and chemotherapy to treat,
private patients under medical insurance and self-pay patients and NHS patients.

Proton Partners will acquire Elekta Versa HD™ (http://www.versahd.com/) systems,
the most modern linear accelerator on the market, as well as Elekta MOSAIQ®
offering a fully integrated OIS consisting of MOSAIQ® radiation
oncology (https://www.elekta.com/software-solutions/care-management/mosaiq
-radiation-oncology.html), MOSAIQ® medical
oncology (https://www.elekta.com/software-solutions/care-management/mosaiq
-medical-oncology/) and MOSAIQ proton therapy. The Versa HD systems and MOSAIQ
software will be installed at the centers in Newport, Wales and Northumberland,
England. The order is valued at more than GBP 5 million and was booked during
Elekta's second fiscal quarter.

Mike Moran, Chief Executive Officer of Proton Partners International, says: “We
are committed to providing the highest quality of treatment at our centers and
as such we are working with class-leading partners. We are pleased to be working
in partnership with Elekta, which is renowned for the excellence of its products
and services.”

Ian Alexander, Chief Commercial Officer at Elekta, says: “We are very pleased to
support Proton Partners in transforming care in the UK. Elekta’s comprehensive,
efficient cancer care management solutions can help Proton Partners to achieve
their goal of treating more than 2,000 patients annually.”

According to Cancer Research UK, the number of new cancer cases each year in the
UK is expected to reach around 432,000 by 2030, and half of these patients
should receive radiotherapy at some point in their treatment. The precision and
speed of Versa HD, it’s advanced beam-shaping, imaging and high dose rate
technologies make it perfect for treating both conventional and complex cancer
cases.

Paddy Greally, Elekta’s Business Unit Manager in the UK & Ireland, adds: “Proton
Partners and Elekta are working together to bring the best and most innovative
radiotherapy to cancer patients in the UK.”

# # #

For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications, Elekta AB
Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com
Time zone: CET: Central European Time

Johan Andersson, Director, Investor Relations, Elekta AB
Tel: +46 702 100 451, e-mail: johan.andersson@elekta.com
Time zone: CET: Central European Time

The above information is such that Elekta AB (publ) shall make public in
accordance with the Securities Market Act and/or the Financial Instruments
Trading Act. The information was published at 07:30 CET on November 30, 2015.
About Elekta
Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated, state-of-the-art tools and treatment planning systems for
radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the boundaries
of science and technology, providing intelligent and resource-efficient
solutions that offer confidence to both health care providers and patients,
Elekta aims to improve, prolong and even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in over 6,000
hospitals worldwide. Elekta employs around 3,800 employees globally. The
corporate headquarters is located in Stockholm, Sweden, and the company is
listed on NASDAQ Stockholm. Website: www.elekta.com.

About Proton Partners International Limited

Proton Partners International is a private limited company, registered in Wales.
The company was formed following discussions between Professor Karol Sikora,
former head of the World Health Organisation’s cancer programme, Professor Sir
Chris Evans, the leading life sciences entrepreneur, and Neil Woodford, founding
partner of Woodford Investment Management. Institutional and private investors
have committed to almost £100m equity finance in the company.

Professor Gordon McVie, Senior Consultant at the European Institute of Oncology,
which partners the Italian Hadron Centre in Pavia, has been appointed chairman
and Professor Karol Sikora is chief medical adviser to the company.

For more information on Proton Partners, please visit: http://proton-int.com/